Aravive Biologics, Inc. today announced that it has been named by FierceBiotech as one of 2017’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
“We are honored to be selected to the “Fierce 15” class of 2017,” said Stephen L. Eck, M.D., Ph.D. President and Chief Executive Officer of Aravive Biologics. “Aravive is committed to developing novel, highly selective cancer therapies based on our understanding of the important role of the tumor microenvironment in cancer. Our company is focused on the promising opportunities that exist in targeting the tumor microenvironment and specifically the Gas6/AXL pathway, which when activated, appears to play a key role in tumor metastasis, modulation of the immune response, and the development of drug resistance.”
“We have an exceptional team with passion for development of innovative drugs to benefit patient care,” added Ray Tabibiazar, M.D., Chairman of Aravive Biologics.
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s fifteenth annual Fierce 15. Each annual selection highlights privately held companies that are working to develop products, services, or platforms that can advance the biotech industry and transform patient treatment. Companies are selected based on a variety of factors such as the strength of their technology, partnerships, venture backers and a competitive market position.
An internationally recognized daily report reaching a network of more than 275,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day’s top stories. Every business day, FierceBiotech and its family of publications covers the waterfront in drug development, from pre‐clinical science to seed funding and venture capital, through IPOs and licensing, clinical testing, regulatory changes, M&A and beyond. FierceBiotech is
a publication of Questex LLC.
About Aravive Biologics, Inc.
Aravive Biologics is a privately held, late pre-clinical stage biopharmaceutical company developing novel, highly selective cancer therapies that treat serious malignancies while sparing normal healthy cells. The company’s lead program is focused on the GAS6/AXL pathway, where activation appears to play a critical role in multiple types of cancer malignancies by promoting tumor metastasis and cell survival. Aravive Biologics has generated strong preclinical data for its lead drug candidate, Aravive-S6, in both acute myeloid leukemia (AML) and solid tumors including ovarian, pancreatic, and breast cancers. The company is based in Houston, Texas, and receives support from the Cancer Prevention & Research Institute of Texas (CPRIT). For more information, please visit our website at http://www.aravive.com.